How useful is chest X-ray in addition to routine QuantiFERON® in the detection of latent tuberculosis prior to biologics?

被引：2

作者：

Kearney, Niamh ^{[1
]}

Aslam, Fawad ^{[2
]}

Boyd, Grace ^{[1
]}

Boylan, Natasha ^{[1
]}

Laverty, Emma ^{[2
]}

O'Hare, Rosie ^{[2
]}

Campbell, Victoria ^{[1
]}

Hoey, Susannah ^{[2
]}

O'Kane, Donal ^{[2
]}

机构：

[1] South Eastern Hlth & Social Care Trust, Ulster Hosp Dundonald, Dept Dermatol, Dundonald, North Ireland

[2] Belfast Hlth & Social Care Trust, Dept Dermatol, Royal Victoria Hosp, Belfast, North Ireland

来源：

CLINICAL AND EXPERIMENTAL DERMATOLOGY | 2024年 / 49卷 / 12期

关键词：

D O I：

10.1093/ced/llae258

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Screening with QuantiFERON (R) /interferon-gamma release assay (IGRA) and chest X-ray (CXR) for latent tuberculosis (TB) infection is recommended by the British Association of Dermatologists prior to commencing some biologics. QuantiFERON is highly sensitive, while CXR is poorly sensitive and poorly specific. In our cohort of 995 patients, 2.3% had a positive IGRA and 8.7% had any abnormality on CXR, with only 0.8% suggestive of TB. Patients were just as likely to have an abnormal CXR if they had a positive or negative IGRA (P = 0.93). We suggest that routine screening with IGRA alone is sufficient in the dermatology population, particularly in the setting of a low TB incidence country such as the UK.

引用

页码：1691 / 1692

页数：2

共 10 条

[1]

British Association of Dermatologists, UK Biologics Checklist

[2] Chest X-ray in suspected lung cancer is harmful [J].

Foley, Robert W. ;

Nassour, Vanessa ;

Oliver, Helen C. ;

Hall, Toby ;

Masani, Vidan ;

Robinson, Graham ;

Rodrigues, Jonathan C. L. ;

Hudson, Benjamin J. .

EUROPEAN RADIOLOGY, 2021, 31 (08) :6269-6274

[3] Immune parameters differentiating active from latent tuberculosis infection in humans [J].

Lee, Ji Yeon ;

Jung, Young Won ;

Jeong, Ina ;

Joh, Joon-Sung ;

Sim, Soo Yeon ;

Choi, Boram ;

Jee, Hyeon-Gun ;

Lim, Dong-Gyun .

TUBERCULOSIS, 2015, 95 (06) :758-763

[4]

National Institute of Health and Care Excellence, Tuberculosis NG33

[5] Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change [J].

Nogueira, M. ;

Warren, R. B. ;

Torres, T. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (04) :824-834

[6] Prevalence and outcomes of incidental imaging findings: umbrella review [J].

O'Sullivan, Jack W. ;

Muntinga, Tim ;

Grigg, Sam ;

Ioannidis, John P. A. .

BMJ-BRITISH MEDICAL JOURNAL, 2018, 361

[7] Comparing the Diagnostic Performance of QuantiFERON-TB Gold Plus to Other Tests of Latent Tuberculosis Infection: A Systematic Review and Meta-analysis [J].

Oh, Chi Eun ;

Ortiz-Brizuela, Edgar ;

Bastos, Mayara L. ;

Menzies, Dick .

CLINICAL INFECTIOUS DISEASES, 2021, 73 (05) :E1116-E1125

[8] National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs) [J].

Rath, Eva ;

Bonelli, Michael ;

Duftner, Christina ;

Gruber, Johann ;

Mandl, Peter ;

Moazedi-Furst, Florentine ;

Pieringer, Herwig ;

Puchner, Rudolf ;

Flick, Holger ;

Salzer, Helmut J. F. ;

Weiss, Guenter ;

Winkler, Stefan ;

Skvara, Hans ;

Moschen, Alexander ;

Hofer, Harald ;

Feurstein, Julia ;

Sautner, Judith .

WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (21-22) :751-765

[9] British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update [J].

Smith, C. H. ;

Yiu, Z. Z. N. ;

Bale, T. ;

Burden, A. D. ;

Coates, L. C. ;

Edwards, W. ;

MacMahon, E. ;

Mahil, S. K. ;

McGuire, A. ;

Murphy, R. ;

Nelson-Piercy, C. ;

Owen, C. M. ;

Parslew, R. ;

Uthman, O. A. ;

Woolf, R. T. ;

Manounah, L. ;

Ezejimofor, M. C. ;

Exton, L. S. ;

Mohd Mustapa, M. F. .

BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) :628-637

[10]

UK Health Security Agency, Tuberculosis (TB) notifications reported to enhanced TB surveillance systems: UK, 2000 to 2023

← 1 →